Revvity Inc vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Revvity Inc trades at $154.33 (market cap $16.98B), while iShares Broad USD Investment Grade Corporate Bond trades at $48.72 (market cap $17.53B). The key difference: Revvity Inc and iShares Broad USD Investment Grade Corporate Bond are close in size by market cap, and Revvity Inc pays a 0.18% dividend while iShares Broad USD Investment Grade Corporate Bond pays none. Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and iShares Broad USD Investment Grade Corporate Bond for 44 Days on average.
| RVTY | USIG | |
|---|---|---|
Market Cap | $16.98B | $17.53B |
Volume | 1,456,900 | 4,695,583 |
Sector | Health | Fixed Income |
52-Week High | $157.36 | $52.69 |
52-Week Low | $82.26 | $48.54 |
Typical Hold Time | 12 Days | 44 Days |
Enterprise Value | $19.30B | — |
Dividend Yield | 0.18% | — |
Signals from Pluang's Aura AI — not financial advice
Revvity (RVTY) trades at $154.33, up 0.48% on the day and near its 52-week high of $158.28. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and positive analyst upgrades reflect solid fundamentals. Key developments include the launch of a new Type 1 diabetes screening kit in Europe and the acquisition of Human Cell Design to bolster metabolic disease research, signaling growth in diagnostics and life sciences.
The outlook remains positive given consistent earnings outperformance and strategic expansions, though rich valuation multiples pose a risk if growth moderates. Investors face near-term headwinds from margin pressures in China and elevated P/E ratios, but institutional accumulation and a lack of sell ratings support a constructive bias for long-term holders.
USIG trades at $48.73 with minimal daily movement (+0.1%). Technical indicators show a bearish bias with moving averages signaling caution, though oscillators are neutral. Recent institutional activity includes Blue Edge Capital's new $21.9 million position and Bank of New York Mellon increasing its stake. The company maintains regular dividend distributions, with recent payments of $0.20-$0.21 per share.
The outlook remains cautious given bearish technical signals and limited fundamental data availability. Investment opportunity exists through dividend income and institutional confidence, but risks include market volatility and the need for clearer financial performance metrics to assess valuation properly.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →